newsfilter
← Latest News
PR Newswire·

Compugen Reports Third Quarter 2026 Results

  • MAIA-ovarian trial for COM701 is fully enrolled with results expected by the end of Q1 2027.
  • Phase 3 high-level results from the ARTEMIDE-Biliary01 trial for partner AstraZeneca's rilvegostomig are anticipated in H2 2027.
  • UnigenX™ was introduced to expand AI-powered discovery into tumor-associated antigens for targeted immune activation modalities like T cell engagers.
  • Cash runway is projected to extend into 2029 with approximately $117.5 million in cash, cash equivalents, investments, and short-term bank deposits as of September 30, 2026.
  • COM701 is being evaluated as a maintenance monotherapy in a global, randomized, placebo-controlled adaptive platform trial for relapsed platinum-sensitive ovarian cancer involving 62 patients.
  • Rilvegostomig is an AstraZeneca-owned PD-1/TIGIT bispecific antibody derived from Compugen's COM902, with potential for up to $195 million in milestone payments & mid-single-digit royalties.
  • AstraZeneca reported favorable median overall survival data for rilvegostomig from the Phase 2 ARTEMIDE-01 trial in September 2026.
  • GS-0321 (formerly COM503), an anti-IL-18 binding protein antibody licensed to Gilead, is advancing in a Phase 1 dose-escalation trial with Compugen eligible for up to $758 million in additional milestones.
  • Third quarter 2026 revenues were approximately $3.8 million compared to $1.9 million in the same period of 2025.
  • Research & development expenses for Q3 2026 were approximately $5.8 million, while general & administrative expenses were approximately $2.3 million.
  • Net loss for Q3 2026 was approximately $5.8 million, or $0.06 per share, compared to a net loss of $7.0 million, or $0.07 per share, in Q3 2025.
  • Compugen held a conference call on November 9, 2026, at 8:30 AM ET to review third quarter 2026 financial results & corporate updates.
Company
Compugen Ltd.
Keywords
Compugen Ltd.